Results 11 to 20 of about 5,550 (180)

JAK2-V617F mutation in patients with myeloproliferative neoplasms: Association with FLT3-ITD mutation [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2010
Introduction. An acquired somatic mutation V617F in Janus kinase 2 gene (JAK2) is the cause of uncontrolled proliferation in patients with myeloproliferative neoplasms.
Čolović Milica, Kostić Tatjana, Pavlović Sonja, Spasovski Vesna, Tošić Nataša   +4 more
doaj   +1 more source

CRISPR/Cas12a-Based Ultrasensitive and Rapid Detection of JAK2 V617F Somatic Mutation in Myeloproliferative Neoplasms

Biosensors, 2021
The JAK2 V617F mutation is a major diagnostic, therapeutic, and monitoring molecular target of Philadelphia-negative myeloproliferative neoplasms (MPNs).
Miaomiao Chen, Chunhua Zhang, Zhiqing Hu, Zhuo Li, Menglin Li, Lingqian Wu, Miaojin Zhou, Desheng Liang   +7 more
doaj   +1 more source

A Comparison of Bone Marrow Morphology and Peripheral Blood Findings in Low and High Level JAK2 V617F Allele Burden

Diagnostics, 2023
Cases with low level JAK2 V617F mutations are increasingly detected; however, the clinical interpretation of the low allele JAK2 burden may be challenging.
Emina Babarović, Blažen Marijić, Luka Vranić, Josipa Ban, Toni Valković, Ita Hadžisejdić   +5 more
doaj   +1 more source

Screening of JAK2 V617F mutation in multiple myeloma [PDF]

Leukemia, 2006
n ...
Fiorini, A, Farina, G, Reddiconto, G, Palladino, M, Rossi, E, Za, T, Laurenti, L, Giammarco, S, Chiusolo, P, Leone, G, Sica, S   +10 more
openaire   +3 more sources

JAK2 V617F Mutation in Patients with Thrombosis

Journal of Advances in Medicine and Medical Research, 2023
Background: Thrombosis is a major disorder with serious complications. The JAK2V617F mutation results in constitutive phosphorylation of JAK2 and activation of the cellular proliferation cascade. The present study aimed to clarify the prevalence of JAK2V617F mutation in patients with thrombosis. Subjects and Methods: This case-control study
Azza Ibrahim Ismail Raslan, Heba Ahmed Mourad, Amira Youssef Ahmed, Atef Mohamed Taha, Mohamed Kamal Zahra   +4 more
openaire   +1 more source

Analysis of JAK2 V617F mutation in Tunisian patients with myeloproliferative neoplasms

European Journal of Inflammation, 2021
We aimed to investigate the prevalence of the JAK2 V617F mutation in Tunisian patients with myeloproliferative neoplasms (MPN) and to look for possible associations with diseases’ presentation. In this context, JAK2 V617F polymorphism was detected by PCR-
Soumaya Chadi, Tarak Dhaouadi, Imen Sfar, Hela Baccouche, Rym Nabli, Neila Ben Romdhane, Taïeb Ben Abdallah, Yousr Gorgi   +7 more
doaj   +1 more source

Chronic Neutrophilic Leukemia with V617F JAK2 Mutation [PDF]

Indian Journal of Hematology and Blood Transfusion, 2012
Chronic neutrophilic leukemia (CNL) is a rare disease grouped under World health organization classification as chronic myeloproliferative disease. It is a diagnosis of exclusion in patients with sustained mature neutrophilia and splenomegaly with no evidence of other myeloproliferative disease or reactive neutrophilia.
Smeeta, Gajendra, Ritu, Gupta, Meenal, Chandgothia, Lalit, Kumar, Richa, Gupta, Snehal Motilal, Chavan   +5 more
openaire   +2 more sources

JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

Haematologica, 2008
Background Refractory anemia with ringed sideroblasts and marked thrombocytosis (RARS-T) was recently shown to be a JAK2-V617F mutation-related disorder.
Annette H. Schmitt-Graeff, Soon-Siong Teo, Manfred Olschewski, Franz Schaub, Sabine Haxelmans, Andreas Kirn, Petra Reinecke, Ulrich Germing, Radek C. Skoda   +8 more
doaj   +1 more source

Thrombotic incidents in patients with myelofibrosis suggest to be independent of JAK2 V617f mutational status [PDF]

Folia Medica, 2022
Introduction: Myelofibrosis (MF) belongs to a group of conditions known as Philadelphia-negative myeloproliferative neoplasms (MPN). Bleeding or various vascular complications could be the main causes of morbidity and mortality in patients with MF ...
Dragomira Nikolova, Atanas Radinov
doaj   +3 more sources

JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms. [PDF]

PLoS ONE, 2010
BACKGROUND: The JAK2 V617F mutation in exon 14 is the most common mutation in chronic myeloproliferative neoplasms (MPNs); deletion of the entire exon 14 is rarely detected.
Wanlong Ma, Hagop Kantarjian, Xi Zhang, Xiuqiang Wang, Zhong Zhang, Chen-Hsiung Yeh, Susan O'Brien, Francis Giles, Jean Marie Bruey, Maher Albitar   +9 more
doaj   +1 more source